Bio-Thera Solutions, Ltd.SSE: 688177

Report for Q3 2025

Oct 29, 2025 · Issued by Bio-Thera Solutions, Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 29, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-607

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Bio-Thera Solutions, Ltd. on 6ix

Earlier from Bio-Thera Solutions

Announcement on Voluntary Disclosure of Progress in the Receipt of the Initial Payment from STADA for the Signing of the Licensing and Commercialization Agreement for BAT1806 (Tocilizumab) InjectionOct 18, 2025
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in CanadaOct 9, 2025
Announcement on the Resignation of Core Technical PersonnelOct 1, 2025
Announcement on Completing Industrial and Commercial Change Registration of Registered Address and Amending the Articles of AssociationSep 24, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors in Guangdong JurisdictionSep 16, 2025

Later from Bio-Thera Solutions

All Bio-Thera Solutions news releases

Follow Bio-Thera Solutions into a list and get an email when it puts out news.

Follow Bio-Thera Solutions